{
    "clinical_study": {
        "@rank": "60492", 
        "acronym": "PESETA", 
        "arm_group": [
            {
                "arm_group_label": "Angioplasty with Zilver PTX", 
                "arm_group_type": "Experimental", 
                "description": "Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX) plus unsupervised exercise therapy, smoking cessation advice and best medical therapy."
            }, 
            {
                "arm_group_label": "Best medical treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Unsupervised exercise therapy, smoking cessation advice and best medical therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized clinical study is intended to evaluate the use of Zilver PTX stents for\n      treatment of thigh atherosclerosis.\n\n      Research question: Is there an adjuvant benefit of angioplasty and stenting using the new\n      paclitaxel eluting stent, Zilver-PTX, over risk factor modification and medical therapy\n      alone in patients with stable, mild to moderate intermittent claudication caused by\n      femoropopliteal lesions suitable for endovascular management."
        }, 
        "brief_title": "Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Arterial Disease", 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has signed and dated the informed consent.\n\n          -  Patient has 1- 2 documented stenotic or occluded atherosclerotic lesions (up to 18 cm\n             long) of the above-the-knee femoropopliteal artery, that meet all of the inclusion\n             criteria and none of the exclusion criteria.\n\n          -  Reference vessel (the above-the-knee femoropopliteal artery) diameter of 4 mm to 9\n             mm.\n\n          -  Taget lesion(s) should be accessible for stenting, as imaged with angiography\n             (digital subtraction, MRI or CTI), i.e. proximal cm of SFA must be open\n\n          -  Patient has a de novo or restenotic lesion(s) with >50% stenosis documented\n             angiographically and no prior stent in the target lesion.\n\n          -  Patient has symptoms of peripheral arterial disease classified as Rutherford Category\n             2 (moderate claudication) or 3 (severe claudication) lasting for at least 3 months.\n             (Positive Claudication Questionnaire)\n\n          -  Exercise therapy, smoking cessation advise and best medical therapy must have been\n             implemented at least 3 months ago and without significant clinical effect.\n\n          -  Patient has a resting ABI <0.9 or an abnormal exercise ABI (decrease of more than\n             0.15) if resting ABI is normal.  Patient with incompressible arteries (ABI >1.2) must\n             have a TBI <0.8.\n\n          -  Patient agrees to return for a clinical status assessment and duplex ultrasound at 6\n             weeks, 6 months, 12 months, and at 24 months.\n\n        Exclusion Criteria:\n\n          -  Patient is pregnant, breast-feeding or under 18 years of age.\n\n          -  Patient unable to understand and sign informed consent forms\n\n          -  Patient is simultaneously participating in another investigational drug or device\n             study.\n\n          -  Patient has any planned surgical or interventional procedure within 30 days after the\n             study procedure.\n\n          -  Patient in whom antiplatelet and/or anticoagulant therapy is contraindicated.\n\n          -  Patient has known hypersensitivity or contraindication to aspirin, antiplatelet\n             medication, contrast dye, paclitaxel or nitinol.\n\n          -  Patient 2-3 patent crural vessel runoff with <50% stenosis throughout its course.\n\n          -  Activity limited by co-morbid condition other than claudication, for example: severe\n             coronary artery disease; angina pectoris; chronic lung disease; neurological disorder\n             such as hemiparesis; arthritis, or other musculoskeletal conditions including\n             amputation and BMI > 40\n\n          -  Other active significant medical problems such as cancer, known chronic renal disease\n             (serum creatinine greater than 2.0 mg/dl within 60 days or renal replacement\n             therapy), known chronic liver disease or anaemia, active substance abuse, or known\n             history of dementia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033135", 
            "org_study_id": "H 4 2012 027"
        }, 
        "intervention": [
            {
                "arm_group_label": "Angioplasty with Zilver PTX", 
                "description": "Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)", 
                "intervention_name": "Angioplasty with Zilver PTX", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Angioplasty with Zilver PTX", 
                    "Best medical treatment"
                ], 
                "description": "Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.", 
                "intervention_name": "Best medical treatment", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Angioplasty with Zilver PTX", 
                "intervention_name": "Zilver PTX", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Atherosclerosis", 
            "Intermittent claudication", 
            "Angioplasty"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "contact": {
                "email": "lpyndt@gmail.com", 
                "last_name": "Lise Pyndt, MD", 
                "phone": "+45 35457458"
            }, 
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "state": "\u00d8sterbro", 
                    "zip": "2100"
                }, 
                "name": "Rigshospitalet"
            }, 
            "investigator": {
                "last_name": "Lise Pyndt, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA)", 
        "overall_contact": {
            "email": "lpyndt@gmail.com", 
            "last_name": "Lise P J\u00f8rgensen, MD,", 
            "phone": "+45 3545 3654"
        }, 
        "overall_contact_backup": {
            "last_name": "Torben V Schroeder, MD, MDSc"
        }, 
        "overall_official": {
            "affiliation": "Dept. of Vasc. Surg., Rigshospitalet, Blegdamsvej 9, 2100 KBH \u00d8, Denmark", 
            "last_name": "Torben V Schroeder, MD, MDSc", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Walking distance will be quantified by standardized treadmill testing using constant speed of 3 km per hour with no incline for a maximum of 5 minutes.", 
            "measure": "Maximal walking distance", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033135"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rigshospitalet, Denmark", 
            "investigator_full_name": "Lise Pyndt J\u00f8rgensen", 
            "investigator_title": "MD, Ph. D. student", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "a measure of the peripheral bloodpressure", 
                "measure": "Ankle brachial pressure indices", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Quality of life is evaluated by using questionnaires", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Cost of the treatment", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Rigshospitalet, Denmark", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rigshospitalet, Denmark", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}